

PROPRANOLOL PREVENTS THE DEVELOPMENT OF VENOUS THROMBOSIS IN RATS BY A PLATELET-DEPENDENT MECHANISM

Maciej Gruszecki, Roland Rólkowski, Robert Pawlak,
Włodzimierz Buczko#*

Department of Pharmacodynamics, Medical Academy of Białystok, Mickiewicza 2C, PL 15-230 Białystok, Poland,

*Department of Laboratory Diagnostics, Regional Centre of Oncology, Warszawska 15, PL 15-062 Białystok, Poland

Propranolol prevents the development of venous thrombosis in rats by a platelet-dependent mechanism. M. GRUSZECKI, R. RÓLKOWSKI, R. PAWLAK, W. BUCZKO. Pol. J. Pharmacol., 2001, 53, 5–10.

To clarify if one of the most common antihypertensive drugs, propranolol, can prevent venous thrombotic process, rats were treated with propranolol (PRO; 5 mg/kg *ip*) in an acute or chronic (14 days) manner. Both regimens resulted in a marked reduction of the systolic blood pressure ($p < 0.001$) and, probably as a consequence, in the shortening of the bleeding time ($p < 0.01$). After ligation of the *vena cava*, the incidence of the venous thrombosis and the thrombus weight decreased significantly in both propranolol-treated groups ($p < 0.01$) when compared to control rats. The anti-thrombotic effect of PRO was not accompanied by any changes in activated partial thromboplastin time, prothrombin time or euglobulin clot lysis time. However, long-term administration of PRO resulted in a reduction of the ADP-induced platelet aggregation.

Key words: *propranolol, venous thrombosis, platelet aggregation, rat*

correspondence